Molecular variant of hairy cell leukemia with poor prognosis.

Abstract:

:Hairy cell leukemia variant (HCLv), described 30 years ago, was reported to present with high disease burden and less often leukopenia, and later was reported to be resistant to purine analogs. Patients with HCLv were overrepresented among patients with HCL seeking relapsed/refractory trials. To compare clinical and molecular features of classic HCL (HCLc) and HCLv, 85 rearrangements expressing immunoglobulin variable heavy chain were sequenced, taken from 20 patients with HCLv and 62 with HCLc. The gene VH4-34, commonly used in autoimmune disorders, was found in eight patients (40%) with HCLv versus six (10%) with HCLc (p = 0.004). Ninety-three percent of the VH4-34 rearrangements were unmutated, defined as >98% homologous to the germline sequence. Clinical features of VH4-34+ patients that were similar to those with HCLv included higher white blood cell counts at diagnosis (p = 0.002) and lower response (p = 0.00001) and progression-free survival (p = 0.007) after first-line cladribine, and shorter overall survival from diagnosis (p < 0.0001). It was found that VH4-34 was independent from HCLv and a stronger predictor than HCLv in associating with poor prognosis. We conclude that VH4-34+ hairy cell leukemia, which only partly overlaps with HCLv, is associated with poor prognosis after single-agent cladribine. However, cases are observed which respond well to antibody therapy either alone or in combination with purine analog.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Arons E,Kreitman RJ

doi

10.3109/10428194.2011.565841

subject

Has Abstract

pub_date

2011-06-01 00:00:00

pages

99-102

eissn

1042-8194

issn

1029-2403

journal_volume

52 Suppl 2

pub_type

杂志文章
  • The role of bone marrow biopsy examination at diagnosis of chronic lymphocytic leukemia: a reappraisal.

    abstract::According to the International Workshop on Chronic Lymphocytic Leukemia/National Institutes of Health (iwCLL/NIH) guidelines for the diagnosis and treatment of chronic lymphocytic leukemia (CLL), bone marrow biopsy (BMB) is not required at diagnosis, however recommended before initiating treatment. That notwithstandin...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2013.780653

    authors: Baliakas P,Kanellis G,Stavroyianni N,Fameli M,Anagnostopoulos A,Stamatopoulos K,Papadaki T

    更新日期:2013-11-01 00:00:00

  • Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience.

    abstract::Tyrosine kinase inhibitors (TKIs) are teratogenic. Chronic myeloid leukemia (CML) is increasingly identified in younger patients who wish to conceive, the management of CML during pregnancy is challenging. We reviewed 51 pregnancies involving 37 patients (30 women, 10 with >1 pregnancy and 7 men) who were either diagn...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1849672

    authors: Assi R,Kantarjian H,Keating M,Pemmaraju N,Verstovsek S,Garcia-Manero G,Ravandi F,Borthakur G,Dahl J,Jabbour E,Cortes JE

    更新日期:2020-12-07 00:00:00

  • Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lymphoma.

    abstract::Pixantrone is a potentially more effective, less cardiotoxic alternative to doxorubicin for patients with aggressive non-Hodgkin lymphoma (aNHL). This phase I/II non-comparative study evaluated pixantrone in place of doxorubicin in the standard CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone),...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2010.546016

    authors: Borchmann P,Herbrecht R,Wilhelm M,Morschhauser F,Hess G,Cernohous P,Veals SA,Singer JW,Engert A

    更新日期:2011-04-01 00:00:00

  • Regression of a plasmablastic lymphoma in a patient with HIV on highly active antiretroviral therapy.

    abstract::We describe an HIV-infected 44-year-old man who presented 1 month after discontinuation of HAART therapy with a large mass extending from the mediastinum, enclosing the heart and extending through the diaphragm to the epigastric region. Biopsies subsequently revealed a highly aggressive non-Hodgkin's lymphoma (NHL) pr...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190290006260

    authors: Nasta SD,Carrum GM,Shahab I,Hanania NA,Udden MM

    更新日期:2002-02-01 00:00:00

  • Quantitative monitoring of BCR--ABL transcript--suggestion of a simplified approach considering inaccuracy of measurement and calibration.

    abstract::According to standard-protocols, real time quantitative RT-PCR (RQ-PCR) for quantification of BCR-ABL fusion transcripts in CML patients is performed with the construction of a standard curve for each run, each sample is analyzed at least in duplicate and 10-40 ml peripheral blood are processed. This approach is appro...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190310001625845

    authors: Röthlisberger B,Herklotz R,Hergersberg M,Stricker C,Bargetzi M,Huber AR

    更新日期:2004-06-01 00:00:00

  • Peripheral blood progenitor cell harvesting in multiple myeloma and malignant lymphoma.

    abstract::Peripheral blood progenitor cells are being used increasingly as part of the treatment protocol for a variety of haematological malignancies. The most appropriate mobilisation therapy and the optimum collection procedures have yet to be fully elucidated. 28 patients with myeloma (9), NHL (11) and HD (8) underwent PBSC...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199509112208

    authors: Scott MA,Ager S,Apperley JF,Jestice HK,Bloxham DM,Boraks P,Mahendra P,Marcus RE

    更新日期:1995-11-01 00:00:00

  • Association of familial leukemia with HLA Cw3: is it real?

    abstract::A kindred with familial leukemia is described in which three members are affected by leukemia in three consecutive generations. One of these members had Philadelphia positive chronic myeloid leukemia (CML) and other two had precursor B acute lymphoblasticleukemia (ALL)--Philadelphia negative. All three of them shared ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819021000035707

    authors: Kuruvilla J,Gupta V,Gill KS,Lipton JH

    更新日期:2003-02-01 00:00:00

  • Amsacrine and continuous-infusion high-dose cytosine arabinoside as induction therapy for patients with newly-diagnosed acute myelogenous leukemia.

    abstract::The overall cure rate of adults with newly-diagnosed acute myelogenous leukemia (AML) treated with continuous infusion high-dose cytarabine (CIHDAC) is comparable to that with standard-dose ara-C plus anthracycline or amsacrine (AMSA). We tested whether the addition of AMSA to CIH-DAC improves the outcome of adults wi...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.3109/10428199609051730

    authors: Ghaddar HM,Pierce S,Kantarjian HM,Freireich EJ,Keating MJ,Estey EH

    更新日期:1996-06-01 00:00:00

  • The role of nuclear medicine in the treatment of non-Hodgkin's lymphoma (NHL).

    abstract::The emergence of radioimmunotherapy (RIT) provides a new therapeutic approach in which monoclonal antibodies directed against tumor-specific antigens are used to target therapeutic radioisotopes to sites of disseminated disease. The target cell is eliminated and adjacent tumor cells, to which antibody has not bound, a...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428140310001616935

    authors: Bischof Delaloye A

    更新日期:2003-01-01 00:00:00

  • Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma.

    abstract::Twenty-nine patients with non-Hodgkin's lymphoma received a single subcutaneous injection of 6 mg pegfilgrastim approximately 24 h after the start of CHOP chemotherapy. The safety of pegfilgrastim in this patient population was determined by reports of adverse events. The pharmacokinetics of pegfilgrastim were charact...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究

    doi:10.1080/1042819031000063462

    authors: George S,Yunus F,Case D,Yang BB,Hackett J,Shogan JE,Meza LA,Neumann TA,Liang BC

    更新日期:2003-10-01 00:00:00

  • Time to post-remission therapy is an independent prognostic factor in adults with acute lymphoblastic leukemia.

    abstract::We evaluated patients with newly diagnosed ALL treated at the Cleveland Clinic during the years 1996 through 2005. Cox proportional hazards analysis was used to identify univariate and multivariate correlates of complete remission, overall survival and progression-free survival. On univariate analysis, significant pro...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190802146078

    authors: Advani AS,Jin T,Ramsingh G,Tiu R,Saber W,Theil K,Sobecks R,Sekeres M,Copelan E,Sungren S,Tripp B,Kalaycio M

    更新日期:2008-08-01 00:00:00

  • Combination treatment of rituximab and imatinib mesylate for simultaneous relapse of MALT lymphoma and a gastrointestinal stromal tumor.

    abstract::A clinical case of patient with a simultaneous gastrointestinal stromal tumors (GIST) and MALT lymphoma in relapse is presented. Simultaneous treatment with imatinib mesylate and rituximab was given, yielded response for both tumors and was well tolerated. ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190412331272712

    authors: Bompas E,Velay B,Blay JY

    更新日期:2004-11-01 00:00:00

  • Up-regulation of tissue inhibitor of metalloproteinase-2 promotes SHI-1 cell invasion in nude mice.

    abstract::The role of tissue inhibitor of metalloproteinase-2 (TIMP-2) in extramedullary infiltration of acute leukemia is unclear. We demonstrated in our previous study that the up-regulation of TIMP-2 promoted SHI-1 cell invasion in vitro. We investigated in the present study whether TIMP-2 would have the same effect in vivo....

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2013.783214

    authors: Wang C,Cai X,Chen B,He Z,Chen Z,Cen J,Li Z

    更新日期:2013-12-01 00:00:00

  • Internal tandem duplications of Flt3 gene (Flt3/ITD) predicts a poor post-remission outcome in adult patients with acute non-promyelocytic leukemia.

    abstract::Despite progress in AML therapy, most patients eventually relapse, even the ones with normal or favorable karyotype. Since survival is poor once relapse occurs, new genetic tools above karyotype at diagnosis are needed to predict leukemia free survival. Recently, Flt3/ITD has been reported as an independent marker for...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819031000151851

    authors: Ciolli S,Vannucchi AM,Leoni F,Nozzoli C,Longo G,Salati A,Pancrazzi A,Bianchi L,Gigli F,Bosi A

    更新日期:2004-01-01 00:00:00

  • Selinexor for advanced hematologic malignancies.

    abstract::Recent measures to classify novel molecular targets with therapeutic potential across multiple hematologic tumors have identified the eukaryotic nuclear exporter, exportin 1 (XPO1), as a promising candidate. Molecular agents termed 'Selective Inhibitors of Nuclear Export' (SINEs) have been developed to selectively inh...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1775210

    authors: Walker JS,Garzon R,Lapalombella R

    更新日期:2020-10-01 00:00:00

  • Immunotherapy for acute myeloid leukemia: from allogeneic stem cell transplant to novel therapeutics.

    abstract::Immunotherapy in the form of allogeneic stem cell transplantation (SCT) plays an instrumental role in the treatment of acute myeloid leukemia (AML), with non-transplant modalities of immunotherapy including checkpoint blockade now being actively explored. Here, we provide an overview of the graft versus leukemia (GVL)...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428194.2019.1639167

    authors: Knorr DA,Goldberg AD,Stein EM,Tallman MS

    更新日期:2019-12-01 00:00:00

  • Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone.

    abstract::The proteasome inhibitor carfilzomib is highly effective in the treatment of multiple myeloma. It irreversibly binds the chymotrypsin-like active site in the β5 subunit of the 20S proteasome. Despite impressive response rates when carfilzomib is used in combination with immunomodulatory agents in newly diagnosed multi...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2016.1214953

    authors: Manasanch EE,de Larrea CF,Zingone A,Steinberg SM,Kwok M,Tageja N,Bhutani M,Kazandjian D,Roschewski M,Wu P,Carter G,Zuchlinski D,Mulquin M,Lamping L,Costello R,Burton D,Gil LA,Figg WD,Maric I,Calvo KR,Yuan C,Stet

    更新日期:2017-03-01 00:00:00

  • Long-term follow-up of Asian patients younger than 46 years with acute myeloid leukemia in first complete remission: comparison of allogeneic vs. autologous hematopoietic stem cell transplantation.

    abstract::Optimal therapy for patients with acute myeloid leukemia (AML) in first complete remission (CR-1) remains the subject of debate: with the possibilities of chemotherapy alone, autologous (auto) or allogeneic (allo) hematopoietic stem cell transplantation (HSCT). We undertook a retrospective analysis of AML patients age...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190601040357

    authors: Loh YS,Koh LP,Tai BC,Hwang WY,Linn YC,Goh YT,Tan PH

    更新日期:2007-01-01 00:00:00

  • Clinical importance of speed of response to therapy in childhood lymphoblastic leukaemia.

    abstract::Speed of response to therapy predicts outcome in childhood lymphoblastic leukaemia. This observation has been made studying both blood and bone marrow in children on widely differing treatment regimens from the 1970s to the present day. It appears to be independent of other classical prognostic factors such as age and...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199809057609

    authors: Lilleyman JS

    更新日期:1998-11-01 00:00:00

  • Role of folate status and methylenetetrahydrofolate reductase genotype on the toxicity and outcome of induction chemotherapy in children with acute lymphoblastic leukemia.

    abstract::The effect of serum folate levels and methylenetetrahydrofolate reductase (MTHFR) genotype on complications and outcome of induction chemotherapy in 150 children with acute lymphoblastic leukemia (ALL) was studied. Folate deficiency in 26% at baseline was more common in children with MTHFR 677 mutations. Folate defici...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2014.947608

    authors: Roy Moulik N,Kumar A,Agrawal S,Awasthi S,Mahdi AA,Kumar A

    更新日期:2015-05-01 00:00:00

  • Measurement of BCR-ABL1 transcripts on the International Scale in the United States: current status and best practices.

    abstract::Chronic myeloid leukemia (CML) results from the Philadelphia chromosome (Ph) translocation and expression of its fusion oncoprotein BCR-ABL1. BCR-ABL1 tyrosine kinase inhibitors (TKIs) are the standard therapy for Ph-positive CML. Achievement of deep molecular responses (typically defined as ≥4-log reduction in BCR-AB...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428194.2016.1190974

    authors: Arora R,Press RD

    更新日期:2017-01-01 00:00:00

  • Successful treatment with Erwinia L-asparaginase for recurrent natural killer/T cell lymphoma.

    abstract::We describe a patient with natural killer (NK)/T cell lymphoma who relapsed after autologous peripheral blood stem cell transplantation (auto-PBSCT) and was successfully treated with Escherichia coli (E. coli) and Erwinia L-asparaginase. A 38-year-old male patient with ulcerated tumor at the left thigh was diagnosed a...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819031000067873

    authors: Matsumoto Y,Nomura K,Kanda-Akano Y,Fujita Y,Nakao M,Ueda K,Horiike S,Yokota S,Kusuzaki K,Kitoh T,Watanabe A,Taniwaki M

    更新日期:2003-05-01 00:00:00

  • Novel agents versus chemotherapy as frontline treatment of CLL.

    abstract::Chronic lymphocytic leukemia (CLL) is a neoplastic disorder of mature B lymphocytes. While traditionally treated with combinations of chemoimmunotherapy, the therapeutic options for CLL have expanded in recent years with the emergence of novel oral agents, such as the Bruton tyrosine kinase inhibitor ibrutinib, that a...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428194.2017.1280606

    authors: Piggin A,Bayly E,Tam CS

    更新日期:2017-06-01 00:00:00

  • Familial Lymphoproliferative Disorders with Chromosomal Fragile Site Analysis.

    abstract::We have identified a family in which three members developed B-cell lymphoproliferative disorders within a nine month period. The 33 year old proband and his mother have hairy cell leukemia, and his 37 year old brother developed a large cell lymphoma. Chromosomal fragile site analysis of peripheral blood lymphocytes o...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199109067623

    authors: Moormeier JA,Neilly ME,Vardiman JW,Le Beau MM,Golomb HM

    更新日期:1991-01-01 00:00:00

  • Evaluation of hemodynamic parameters among patients with myeloproliferative neoplasms and suspected pulmonary hypertension.

    abstract::Myeloproliferative neoplasms (MPNs) are associated with pulmonary hypertension (PH). We studied MPN patients who underwent right-heart-catheterization (RHC) to identify hemodynamic differences between MPN-subtypes. Per RHC, hemodynamics were classified as pre, post or combined pre and post-capillary PH. One-way analys...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1864351

    authors: Khan NA,Ahuja KA,Wang X,Chaisson NF

    更新日期:2021-01-25 00:00:00

  • Acute megakaryocytic leukemia with the t(1;22)(p13;q13).

    abstract::Acute megakaryocytic leukemia (AMKL) was defined as a new subtype of acute nonlymphocytic leukemia (ANLL) by the French-American-British (FAB) Cooperative Group in 1985. The first consistent chromosomal anomaly described in this subset of ANLL was the translocation t(1;22)(p13;q13) which appears to be restricted to th...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199309054726

    authors: Lion T,Haas OA

    更新日期:1993-09-01 00:00:00

  • Acute trilineage leukemia with monosomy of chromosome 7 following an acute promyelocytic leukemia.

    abstract::We describe an 8 year old boy who had received chemotherapy for an acute promyelocytic leukemia and developed a secondary leukemia 27 months after the diagnosis of this first malignancy. Blasts cells were positive for cytoplasmic markers CD22, CD3 and myeloperoxidase. Cell surface T and myeloid-associated markers were...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199909050968

    authors: Felice MS,Rossi J,Gallego M,Zubizarreta PA,Cygler AM,Alfaro E,Sackmann-Muriel F

    更新日期:1999-07-01 00:00:00

  • The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide.

    abstract::Patients with multiple myeloma who are refractory or intolerant to both bortezomib and lenalidomide have a poor prognosis. Next-generation therapies carfilzomib and pomalidomide have shown promising activity in this dual refractory population. Here we describe the clinical characteristics and ascertain the effects of ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2013.803547

    authors: Wang TF,Ahluwalia R,Fiala MA,Trinkaus KM,Cox DP,Jaenicke M,Moliske CC,Carson KR,Wildes TM,Tomasson MH,Stockerl-Goldstein KE,Vij R

    更新日期:2014-02-01 00:00:00

  • Is the CHOP regimen a good treatment for advanced CLL? Results from two randomized clinical trials. French Cooperative Group on Chronic Lymphocytic Leukemia.

    abstract::Between 1985 and 1990, the French Cooperative Group on Chronic Lymphocytic Leukemia (CLL) randomized 287 stage B patients between intermittent chlorambucil plus prednisone (n = 140) or CHOP (n = 147), and 90 stage C patients between CHOP (n = 44) or CHOP plus methotrexate (n = 46). In stage B, although treatment respo...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.3109/10428199409049634

    authors:

    更新日期:1994-05-01 00:00:00

  • Abundant expression of interleukin-21 receptor in follicular lymphoma cells is associated with more aggressive disease.

    abstract::Recombinant interleukin-21 (IL-21) has potential utility in cancer therapy. Stimulation with IL-21 can induce apoptosis in follicular lymphoma (FL) cells, and existing studies have suggested that IL-21 signaling may function in tumor suppression. In order to elucidate the relationship between IL-21 receptor (IL-21R) e...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2012.742522

    authors: Wood B,Sikdar S,Choi SJ,Virk S,Alhejaily A,Baetz T,LeBrun DP

    更新日期:2013-06-01 00:00:00